Best GLP-1 for Prediabetes Prevention: Can Semaglutide Stop Type 2 Diabetes?

Prediabetes: The Scale of the Problem

Prediabetes is defined by blood glucose levels above normal but below the threshold for type 2 diabetes diagnosis. Fasting blood glucose between 100 and 125 mg/dL, or HbA1c between 5.7% and 6.4%, indicates prediabetes by current American Diabetes Association criteria. The condition is not benign: it reflects underlying insulin resistance, impaired beta-cell function, and early cardiovascular changes that are already underway before frank diabetes is diagnosed.

Approximately 98 million American adults — about 38% of the adult population — have prediabetes as of 2026. More concerning, approximately 84% of them are unaware of their condition. Without intervention, 15 to 30 percent of people with prediabetes will develop type 2 diabetes within five years, and the majority will develop it over a longer time horizon. The cardiovascular risk conferred by prediabetes begins before diabetes diagnosis: people with prediabetes already show elevated rates of heart disease, stroke, kidney disease, and neuropathy compared to normoglycemic individuals.

The traditional approach to prediabetes has been lifestyle intervention — dietary changes, increased physical activity, and modest weight loss. The landmark Diabetes Prevention Program (DPP) clinical trial demonstrated that a structured lifestyle program producing 5 to 7 percent weight loss reduced progression to type 2 diabetes by 58% over three years. This was a meaningful result, but it came with an important caveat: achieving and maintaining even 5 to 7 percent weight loss through lifestyle alone proved extremely difficult for most participants. Real-world adherence to lifestyle interventions is significantly lower than trial conditions, and long-term maintenance of achieved weight loss is the exception rather than the rule without pharmacological support.

GLP-1 medications offer a fundamentally different approach to prediabetes prevention: rather than relying entirely on behavioral change to achieve modest weight loss, they produce clinically significant and sustained weight reduction alongside direct improvements in beta-cell function and insulin sensitivity. The result is a more powerful and sustained attack on the metabolic dysfunction driving diabetes progression.

Semaglutide's Evidence for Prediabetes Prevention

Multiple clinical trials provide evidence for semaglutide's role in preventing type 2 diabetes in high-risk individuals. The most compelling data comes from the STEP program and the SELECT cardiovascular outcomes trial.

STEP Program: Prediabetes Reversal Data

The STEP 1 trial enrolled adults with obesity or overweight plus comorbidities, with no type 2 diabetes. At baseline, approximately one-third of participants had prediabetes. After 68 weeks of treatment with semaglutide 2.4 mg, the proportion of participants with prediabetes declined from 33% to just under 9% — meaning roughly three-quarters of participants who entered the trial with prediabetes no longer met prediabetes criteria after treatment.

The STEP 5 trial, which followed participants for 104 weeks (two years), provided even longer-term diabetes prevention data. At two years, 61% of participants who had prediabetes at baseline had achieved normoglycemia — normal blood glucose levels — while on semaglutide 2.4 mg. This is a remarkable outcome: more than half of patients with prediabetes essentially normalized their metabolic status within two years of treatment.

The SELECT Trial: A Landmark Diabetes Prevention Signal

The SELECT trial was primarily designed to assess cardiovascular outcomes, but its diabetes prevention data represented a historic finding. SELECT enrolled 17,604 adults with overweight or obesity and pre-existing cardiovascular disease — a population at extremely high risk for developing type 2 diabetes. None had diabetes at baseline.

Over a median follow-up of approximately 33 months, participants on semaglutide 2.4 mg experienced a 73% lower incidence of new-onset type 2 diabetes compared to placebo. This was not a pre-specified primary endpoint but emerged as a striking secondary finding that substantially expanded understanding of semaglutide's preventive potential. In a population with baseline cardiovascular disease, where diabetes incidence is high and its consequences are severe, a 73% risk reduction represents a genuinely transformative intervention.

Detailed analysis of SELECT data suggested that the diabetes prevention benefit was only partially attributable to weight loss. Even after adjusting for body weight changes, semaglutide retained independent protective effects on glycemia, suggesting that its direct actions on beta-cell function, hepatic glucose metabolism, and insulin sensitivity contribute to diabetes prevention beyond what weight loss alone would predict. For a complete review of SELECT trial findings, see our cardiovascular benefits hub.

Mechanisms: How GLP-1 Prevents Diabetes

Understanding why GLP-1 medications are so effective at preventing diabetes requires appreciating that semaglutide acts on prediabetes through multiple independent pathways, not just through weight loss.

The first and most widely discussed mechanism is weight loss. Adipose tissue — particularly visceral fat — drives insulin resistance through the secretion of inflammatory cytokines and free fatty acids. As body weight falls, this inflammatory burden decreases, peripheral insulin sensitivity improves, and the liver reduces its excess glucose output. Even a 5% reduction in body weight produces measurable improvements in insulin sensitivity; the 15 to 17% average weight loss achieved with semaglutide 2.4 mg far exceeds this threshold and produces correspondingly profound metabolic improvements.

The second mechanism involves direct beta-cell protection. Pancreatic beta cells — the insulin-producing cells whose dysfunction drives both prediabetes and type 2 diabetes — express GLP-1 receptors. Pharmacological GLP-1 receptor activation stimulates glucose-dependent insulin secretion, protects beta cells from apoptosis (programmed cell death), and appears to stimulate beta-cell proliferation and restoration of lost beta-cell mass in some preclinical models. This means semaglutide may not only slow the loss of beta-cell function but may partially restore function that was lost before treatment began.

The third mechanism is reduction of hepatic glucose production. Semaglutide activates GLP-1 receptors in the liver, reducing the excess hepatic glucose output that contributes to fasting hyperglycemia in prediabetes. This effect is independent of insulin secretion and provides additional glycemic control particularly relevant to the elevated fasting glucose that characterizes early prediabetes.

Finally, semaglutide's appetite suppression and food intake reduction reduce postprandial glucose excursions — the blood sugar spikes after meals that drive progressive beta-cell damage over time. By limiting the magnitude and frequency of postprandial hyperglycemia, semaglutide reduces glucotoxicity — the cycle by which elevated blood glucose damages the beta cells responsible for controlling it. This is an important mechanism for understanding why semaglutide's glucose benefits exceed what weight loss alone would predict.

Patients interested in tracking these metabolic improvements directly may benefit from continuous glucose monitoring during treatment. See our guide on using CGM with GLP-1 medications for a practical overview.

Semaglutide vs. Tirzepatide for Prediabetes Prevention

When considering GLP-1 medications for prediabetes prevention, the choice frequently comes down to semaglutide versus tirzepatide. Both are highly effective, but they differ in mechanism, magnitude of metabolic effects, and available evidence specific to diabetes prevention.

Semaglutide has the stronger and more specific evidence base for diabetes prevention in non-diabetic patients, particularly through the SELECT trial data. Tirzepatide's dual GIP/GLP-1 mechanism produces superior average weight loss (20–22% vs 15–17%) and greater A1c and fasting glucose reductions in head-to-head comparisons in type 2 diabetes patients (the SURPASS-2 trial). In patients with prediabetes, tirzepatide's superior metabolic effects strongly suggest it would produce at least comparable, and potentially superior, diabetes prevention — though direct comparative trial data in non-diabetic prediabetes populations is not yet available.

For most patients with prediabetes and overweight or obesity, either medication represents an evidence-based choice. Patients with additional cardiovascular risk factors may particularly benefit from semaglutide given its robust cardiovascular outcomes data from SELECT. Patients with severe insulin resistance or metabolic syndrome may derive additional benefit from tirzepatide's GIP-mediated improvements in insulin sensitivity. See our detailed tirzepatide vs semaglutide comparison for a complete breakdown.

The A1c monitoring context is important here. Patients on GLP-1 medications for prediabetes prevention should have HbA1c and fasting glucose checked at baseline and periodically during treatment to document response and confirm that glucose levels are improving rather than progressing. Our guide to A1c changes on GLP-1 medications explains what to expect over time.

Getting Access Through Trimi: Prediabetes as a Qualifying Comorbidity

FDA approvals for semaglutide 2.4 mg (Wegovy) and tirzepatide (Zepbound) for weight management require a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity. Prediabetes is explicitly recognized as a qualifying weight-related comorbidity, meaning that most patients with prediabetes and meaningful overweight are medically eligible for GLP-1 therapy for weight management and its consequent diabetes prevention benefits.

Trimi provides compounded semaglutide starting at $99/month and compounded tirzepatide starting at $125/month, with licensed provider evaluation and ongoing support included. The medical intake process captures fasting glucose and HbA1c history, allowing providers to identify patients with prediabetes and tailor treatment appropriately. Patients with prediabetes do not require a diabetes diagnosis to access GLP-1 therapy — their elevated glucose alone qualifies as the comorbidity that supports treatment.

Patients considering GLP-1 therapy for prediabetes prevention should also review the monitoring recommendations in our blood tests before starting GLP-1 guide and the ongoing monitoring guide for labs to track while on GLP-1 therapy. These guides help patients understand what baseline testing supports their treatment and what ongoing labs confirm that the medication is producing the intended metabolic benefits.

Frequently Asked Questions